Intensity Therapeutics (INTS) Proxy Filing summary

Executive summary

• Special Meeting scheduled for October 22, 2025, to be held virtually for increased participation and efficiency.

• Stockholders will vote on a reverse stock split and potential adjournment if more votes are needed.

• The reverse stock split aims to address Nasdaq's minimum bid price requirement and improve marketability.

• Board recommends voting in favor of both proposals.

Voting matters and shareholder proposals

• Proposal 1: Approve an amendment to effect a reverse stock split at a ratio between 1-for-5 and 1-for-30, with the exact ratio set by the board.

• Proposal 2: Approve adjournment of the meeting if more time is needed to solicit votes for Proposal 1.

• Both proposals are considered routine matters, allowing brokers discretionary voting authority.

• Board unanimously recommends voting "FOR" both proposals.

Board of directors and corporate governance

• Board retains discretion to implement or abandon the reverse stock split even if approved by stockholders.

• Communication procedures for stockholders to contact the board are outlined.

• No director or executive officer has a substantial interest in the reverse stock split beyond their share ownership.